Abstract
Purpose
Noninvasive imaging of tau and amyloid-β pathologies would facilitate diagnosis of Alzheimer’s disease (AD). Recently, we have developed [18F]THK-5105 for selective detection of tau pathology by positron emission tomography (PET). The purpose of this study was to clarify biological properties of optically pure [18F]THK-5105 enantiomers.
Procedures
Binding for tau aggregates in AD brain section was evaluated by autoradiography (ARG). In vitro binding assays were performed to evaluate the binding properties of enantiomers for AD brain homogenates. The pharmacokinetics in the normal mouse brains was assessed by ex vivo biodistribution assay
Results
The ARG of enantiomers showed the high accumulation of radioactivity corresponding to the distribution of tau deposits. In vitro binding assays revealed that (S)-[18F]THK-5105 has slower dissociation from tau than (R)-[18F]THK-5105. Biodistribution assays indicated that (S)-[18F]THK-5105 eliminated faster from the mouse brains and blood compared with (R)-[18F]THK-5105.
Conclusion
(S)-[18F]THK-5105 could be more suitable than (R)-enantiomer for a tau imaging agent.
Similar content being viewed by others
References
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189
Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biology 8:101–12
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–6
Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112–9
Jack CR, Knopman DS, Jagust WJ et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–16
Rowe CC, Villemagne VL (2013) Brain amyloid imaging. J Nucl Med Tech 41:11–8
Villemagne V, Furumoto S, Fodero-Tavoletti MT et al (2012) The challenges of tau imaging. Future Neurol 7:409–421
Svedberg MM, Rahman O, Hall H (2012) Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer’s disease. Nucl Med Biol 39:484–501
Jensen JR, Cisek K, Funk KE et al (2011) Research towards tau imaging. J Alzheimer’s Dis 26:147–57
Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131:1630–45
Clark CM, Schneider JA, Bedell BJ et al (2011) Use of florbetapir-PET for imaging. JAMA 305:275–284
Wolk DA, Grachev ID, Buckley C et al (2011) Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 68:1398–403
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42:631–631
Akoury E, Pickhardt M, Gajda M et al (2013) Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew Chem Int Ed 52:3511–5
Chien DT, Bahri S, Szardenings AK et al (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimer’s Dis 34:457–68
Zhang W, Arteaga J, Cashion DK et al (2012) A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimer’s Dis 31:1–12
Kepe V, Bordelon Y, Boxer A et al (2013) PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimer’s Dis 36:145–53
Maruyama M, Shimada H, Suhara T et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108
Okamura N, Suemoto T, Furumoto S et al (2005) Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease. J Neurosci 25:10857–62
Fodero-Tavoletti MT, Okamura N, Furumoto S et al (2011) 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 134:1089–100
Harada R, Okamura N, Furumoto S et al (2013) Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging 40:125–132
Tago T, Furumoto S, Okamura N et al (2014) Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. J Labelled Compd Radiopharm 57:18–24
Okamura N, Furumoto S, Harada R et al (2013) Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54:1420–7
Okamura N, Furumoto S, Fodero-Tavoletti MT et al (2014) Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137:1762–71
Simonyi M, Fitos I, Visy J (1986) Chirality of bioactive agents in protein binding storage and transport processes. Trends Pharmacol Sci 7:112–116
Nau C, Strichartz GR (2002) Drug chirality in anesthesia. Anesthesiology 97:497–502
Mizuta T, Kitamura K, Iwata H et al (2008) Performance evaluation of a high-sensitivity large-aperture small-animal PET scanner: ClairvivoPET. Ann Nucl Med 22:447–55
Graham TJ, Lambert RF, Ploessl K et al (2014) Enantioselective radiosynthesis of positron emission tomography (PET) tracers containing [18F]fluorohydrins. J Am Chem Soc 136:5291–4
Bulic B, Pickhardt M, Mandelkow E (2013) Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem 56:4135–55
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–59
Forsberg A, Juréus A, Cselényi Z et al (2013) Low background and high contrast PET imaging of amyloid-β with [(11)C]AZD2995 and [ (11)C]AZD2184 in Alzheimer’s disease patients. Eur J Nucl Med Mol Imaging 40:580–93
Mathis CA, Wang Y, Holt DP et al (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740–2754
Ishiwata K, Kawamura K, Yanai K, Hendrikse NH (2007) In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med 48:81–7
Barraud de Lagerie S, Comets E, Gautrand C et al (2004) Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br J Pharmacol 141:1214–22
Price JC, Klunk WE, Lopresti BJ et al (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25:1528–47
Nguyen LA, He H, Pham-Huy C (2006) Chiral drugs: an overview. Int J Biomed Sci 2:85–100
Matsumura A, Mizokawa S, Tanaka M et al (2003) Assessment of microPET performance in analyzing the rat brain under different types of anesthesia: comparison between quantitative data obtained with microPET and ex vivo autoradiography. NeuroImage 20:2040–2050
Acknowledgments
We thank all the staff at Cyclotron Radioisotope Center of Tohoku University for the HM-12 cyclotron operation. This study was supported by the Industrial Technology Research Grant Program of the NEDO in Japan (09E51025a), a Grant-in-Aid for Scientific Research (B) (25293259), and Health and Labour Sciences Research Grants from the Ministry of Health, Labour, and Welfare of Japan.
Conflict of Interest
Research funds for this study were provided by GE Healthcare, CLINO Co. Ltd., the SEI (Sumitomo Electric Industries, Ltd.) Group CSR Foundation. S. Furumoto, N. Okamura, and Y. Kudo are scientific consultants for the CLINO Co. Ltd.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 286 kb)
Rights and permissions
About this article
Cite this article
Tago, T., Furumoto, S., Okamura, N. et al. Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer. Mol Imaging Biol 18, 258–266 (2016). https://doi.org/10.1007/s11307-015-0879-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-015-0879-8